Cholinergic synapses are ubiquitous in the human central nervous system. Their high
density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic …

Quercetin is a flavonoid with notable pharmacological effects and promising therapeutic
potential. It is widely distributed among plants and found commonly in daily diets …

Alzheimer's disease (AD) is a neurodegenerative disorder with devastating symptoms,
including memory impairments and cognitive deficits. Hallmarks of AD pathology are …

The foundation of current Alzheimer's disease (AD) treatment involves pharmacological and
nonpharmacological management and care planning predicated on patient-centered …

Dementia is a devastating disease that places a significant physical, emotional and financial
burden on patients, their caregivers and society. About 564,000 Canadians have dementia …

ABSTRACT The US Food and Drug Administration (FDA)'s recent accelerated approval of
two anti-amyloid antibodies for treatment of Alzheimer's disease (AD), aducanumab and …

Alzheimer's disease (AD) is the leading cause of dementia worldwide. Even though the
number of AD patients is rapidly growing, there is no effective treatment for this …

Alzheimer's disease (AD) is the most common cause of cognitive impairment or dementia in
individuals older than 65 years and, with rising longevity, a worldwide pandemic of mild …

Memantine, a partial antagonist of N-methyl-D-aspartate receptor (NMDAR), approved for
moderate to severe Alzheimer's disease (AD) treatment within the US and Europe under …

Alzheimer's disease (AD) is the most common form of dementia. It is characterized by
extracellular deposition of a specific protein, beta-amyloid peptide fibrils, and is …